Angiotensin-converting enzyme (ACE) inhibitors are the mainstay of therapy for patients with systemic sclerosis in scleroderma renal crisis, however mortality remains high even in the post-ACE ...

Researchers have found in a new retrospective study that cough related to ACE inhibitor use in children may be more prevalent than previously recognized, but it is typically mild, well ...

ACE inhibitor use delays development of renal involvement in patients with systemic lupus erythematosus (SLE). In a study of 378 SLE patients, 80 (21%) were ACE inhibitor users and 298 (79%) were not.

Thus, ACE inhibitors appear not to mediate angioedema through an allergic or idiosyncratic reaction; rather, they seem to facilitate angioedema in predisposed individuals. Despite the aforementioned ...

March 24, 2011 (Edmonton and Calgary, Alberta) — In clinical practice and as has been seen in clinical trials, combining an angiotensin-converting enzyme (ACE) inhibitor with an angiotensin-receptor ...

For immediate post-MI patients, sacubitril/valsartan (Entresto; Novartis) does not significantly decrease the risk of heart failure (HF) or CV death compared with an ACE inhibitor, the PARADISE-MI ...

Since the introduction of ARBs, the question that has pervaded each clinician’s mind is whether or not these drugs serve an advantage in conditions long addressed by ACE inhibitors. Matchar et al ...

Patients with heart failure who start taking sacubitril/valsartan (Entresto; Novartis) do not appear to have a greater risk of angioedema than do those who opt for an ACE inhibitor or ARB instead, an ...